# A Study Evaluating the Bioequivalence of VIAject®7 Compared to VIAject®25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject®7 to Insulin Lispro in Subjects With Type 1 Diabetes Mellitus

> **NCT01235039** · PHASE1,PHASE2 · COMPLETED · sponsor: **Biodel** · enrollment: 43 (actual)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** VIAject®25
- **DRUG:** VIAject®7
- **DRUG:** Insulin Lispro

## Key facts

- **NCT ID:** NCT01235039
- **Lead sponsor:** Biodel
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2009-09
- **Final completion:** 2009-09
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2015-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01235039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01235039, "A Study Evaluating the Bioequivalence of VIAject®7 Compared to VIAject®25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject®7 to Insulin Lispro in Subjects With Type 1 Diabetes Mellitus". Retrieved via AI Analytics 2026-09-26 from https://api.ai-analytics.org/clinical/NCT01235039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*